Durga Manjari Arvapalli – Seminar/PhD Preliminary Defense – Monday, November 27, 2017 at 1:00 P.M.
JSNN – Durga Manjari Arvapalli – Ph.D. Preliminary Defense/Monday Seminar
Candidate: Durga Manjari Arvapalli
Advisor and Committee Chair: Jianjun Wei, Ph.D.
Time: 1:00 P.M. – 3:00 P.M.
Location: JSNN 209 Open Room2907 E. Gate City Blvd., Greensboro, NC 27401
Title: “Carbon Nanodots (CNDs) based Nanotheranostics for Treatment of Hepatocellular Carcinoma (HCC) Integrated with Lab on a Chip Studies.”
Cancer deaths are predominant in the United States with 24% of men and 21% of women are estimated to be diagnosed with cancer by 2020. Despite advances in the respective technologies and novel therapeutic strategies under investigation, an optimal more effective therapeutic treatment strategy with reduced risks and side effects has yet to be discovered. Microfluidics can be a valuable tool for cancer investigation in maintaining tumor microenvironment due to its high sensitivity, less material-consumption, low cost, and enhanced spatio-temporal control. And also, the continuous fluid motion supplying nutrients and oxygen to cells closely mimics the 3D tumor microenvironment inside the human body that can facilitate high-throughput drug screening. Carbon Nanodots (CNDs) serve as promising carbon-based imaging delivery probes with excellent biocompatibility, water solubility, and photo stability. Curcumin, a natural spice with anti-inflammatory and anti-cancer properties has promising role in treatment of cancer. Despite its safety and efficacy, curcumin clinical applications are hampered by its poor aqueous solubility and oral bioavailability in Humans. Nanoformulations of Curcumin can address the outlined problem. CNDs were functionalized with Curcumin to target Liver cancer cells, HepG2. Functionalizing the CNDs with Curcumin makes them a promising theranostic agent in the treatment of Liver cancer, as CNDs have been luminescent and Curcumin has natural anti-oxidant and anti-tumor properties. Moreover, tagging the Curcumin functionalized with Folic acid specifically targets the particles towards the cancer cells, as cancer cells express high levels of Folic acid receptors on their surface. Development of this novel theranostic nanoagent with low toxicity can offer promising diagnosis and effective targeted treatment of liver cancer at an early stage.